FindTrial
Sign In

Efficacy of Dashamoola Rasayana in mild to moderate stable Chronic Obstructive Pulmonary Disease against Conventional Modern Medications - A Comparative Randamised Clinical Trial.

Efficacy of Dashamoola Rasayana in mild to moderate stable Chronic Obstructive Pulmonary Disease against Conventional Modern Medications - A Comparative Randamised Clinical Trial. - RACE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086102
Enrollment
100
Registered
2025-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

None listed

Sponsors

GLOCAL UNIVERSITY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of Either Sex, age between 16yr-70yr Informed consult provided Subjects Selection of the patients will done on the basis of three criteria viz. Selection of the patients will done on the basis of three criteria viz. Symptomatological criteria, Radiological and Spirometric criteria (given by GOLD 202431 )

Exclusion criteria

Exclusion criteria: Severe COPD31(GOLD stage III and IV). GOLD ABE category E31 patients Patients suffering from major systemic illness necessitating long term drug treatment and patients with clinical evidence of heart failure. Patients suffering from other pulmonary diseases like pneumonia, cystic fibrosis, tuberculosis, lung cancer etc Patient suffering from Diabetes mellitus Patient Suffering from Chronic Kidney Diseases

Design outcomes

Primary

MeasureTime frame
The primary outcome, as mentioned, is often the annual decline in lung function (FEV1), which indicates the progression of airflow obstructionTimepoint: 1 year—

Secondary

MeasureTime frame
Exacerbation Rates: The frequency of COPD flare-ups, which are periods of worsening symptoms requiring treatment. Respiratory Symptoms: Changes in symptoms like shortness of breath, cough, and wheezing.Timepoint: 2 to 3 months—

Countries

India

Contacts

Public ContactRaghavendra Y

Glocal Ayurveda University,

raghu.y001@gmail.com8762885599

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026